<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04598932</url>
  </required_header>
  <id_info>
    <org_study_id>20-355</org_study_id>
    <nct_id>NCT04598932</nct_id>
  </id_info>
  <brief_title>Corneal Biomechanical Analysis Using Brillouin Microscopy</brief_title>
  <official_title>Corneal Biomechanical Analysis Using Brillouin Microscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Maryland, College Park</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to measure the Brillouin biomechanical properties in&#xD;
      keratoconic corneas and characterize biomechanical alterations that occur after corneal&#xD;
      procedures that inherently strengthen or weaken the cornea by evaluating the change in&#xD;
      Brillouin metrics before and after treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgical correction of myopia and keratoconus identification/management are separate but&#xD;
      tightly intertwined issues of major significance. For both, there is an unmet need for direct&#xD;
      measurements to evaluate corneal stiffness (i.e. its resistance to deformation). The&#xD;
      prevalence of myopia is expected to double, affecting more than 50% of the US population, by&#xD;
      2050. Laser in situ keratomileusis (LASIK) is one of the most popular and successful&#xD;
      surgeries in the world and compares favorably to long-term contact lens wear use for myopia&#xD;
      correction. However, only ~10% of eligible patients undergo LASIK currently; the others cite&#xD;
      safety concerns as a major factor in their decision. The primary risk for poor refractive&#xD;
      surgery outcomes is biomechanical failure due to unidentified (subclinical) ectasia (i.e.&#xD;
      keratoconus). Patients presenting for LASIK evaluation with atypical, suspicious corneal&#xD;
      curvature but with undetermined true risk represent the leading reason for surgery screening&#xD;
      failures. This results in good candidates being denied surgery, while up to 10% of truly poor&#xD;
      candidates are still missed using current screening algorithms.&#xD;
&#xD;
      Keratoconus is up to 10 times more prevalent than the previously reported 1/2000 figure.&#xD;
      Corneal cross-linking (CXL) is now FDA approved in the US for keratoconus treatment and is&#xD;
      effective at stiffening the cornea and halting ectasia progression. Early identification of&#xD;
      keratoconus is critical, but current tests in the clinic are morphological, not&#xD;
      biomechanical, and therefore do not allow a definitive diagnosis at the earliest stages&#xD;
      resulting in vision loss before CXL treatment is initiated. Thus, the need for accurate&#xD;
      identification of subclinical ectasia has never been greater.&#xD;
&#xD;
      In the past years, newly developed technology, Brillouin microscopy, has emerged as the most&#xD;
      promising tool to address this clinical need. This study will systemically address the&#xD;
      critical gap in current knowledge by linking Brillouin mapping of corneal biomechanical&#xD;
      alterations to abnormal morphological behavior and testing the findings in conditions where&#xD;
      corneal biomechanics are abruptly altered, by: 1) weakening with refractive surgery&#xD;
      procedures, and 2) strengthening through corneal cross-linking.&#xD;
&#xD;
      It is anticipated that a clinical tool assessing the mechanical state of the cornea will&#xD;
      improve early diagnosis and management of keratoconus as well as refractive surgery planning.&#xD;
      Ultimately, this will lead to predictive models where Brillouin measurements could be an&#xD;
      accurate predictor of postoperative outcomes and thus aid in developing individualized&#xD;
      surgical parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Brillouin Metrics</measure>
    <time_frame>Difference between baseline and 3 months after intervention</time_frame>
    <description>Brillouin metrics to be evaluated include localized Mean Brillouin modulus measure across the cornea and at each depth of the corneal stroma</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Keratoconus</condition>
  <condition>Keratoconus, Unstable</condition>
  <condition>Keratoconus, Stable</condition>
  <arm_group>
    <arm_group_label>1: Normal Controls</arm_group_label>
    <description>Patients with normal corneas without any prior surgery to serve as the control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Keratoconus</arm_group_label>
    <description>Patients with various stages of keratoconus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: LASIK</arm_group_label>
    <description>Patients with normal corneas who are undergoing laser in situ keratomileusis (LASIK)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: PRK</arm_group_label>
    <description>Patients with normal corneas who are undergoing photorefractive keratectomy (PRK)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5: SMILE</arm_group_label>
    <description>Patients with normal corneas who are undergoing small incision lenticular extraction (SMILE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6: CXL</arm_group_label>
    <description>Patients with keratoconus who are undergoing corneal cross-linking (CXL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Brillouin microscopy</intervention_name>
    <description>The Brillouin clinical instrument is comprised of three parts: a human interface, a laser-scanning confocal microscope, and an etalon-based spectrometer. The human interface is a modified ophthalmic slit-lamp instrument with chin support and headrest. The light source is a single longitudinal mode CW laser at 780 nm. A polarizing beam splitter and quarter-wave plate assembly sends the laser beam to the human interface. To focus light into the eye, a long-working distance microscope objective is used. Brillouin scattered light from the eye is collected with a single-mode optical fiber. For spectral analysis, a two-stage VIPA-etalon spectrometer configured with the cross-axis cascade principle and the spectrum is measured on a EM-CCD camera.</description>
    <arm_group_label>1: Normal Controls</arm_group_label>
    <arm_group_label>2 Keratoconus</arm_group_label>
    <arm_group_label>3: LASIK</arm_group_label>
    <arm_group_label>5: SMILE</arm_group_label>
    <arm_group_label>6: CXL</arm_group_label>
    <arm_group_label>Group 4: PRK</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Group 1: Patients with normal corneas Group 2: Patients with keratoconus Group 3: Patients&#xD;
        with normal corneas undergoing LASIK Group 4: Patients with normal corneas undergoing PRK&#xD;
        Group 5: Patients with normal corneas undergoing SMILE Group 6: Patients with keratoconus&#xD;
        undergoing CXL&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients aged 18-60 with keratoconus&#xD;
&#xD;
          -  patients aged 18-60 with normal corneas,&#xD;
&#xD;
          -  patients aged 18-60 undergoing refractive surgery (LASIK, PRK, SMILE)&#xD;
&#xD;
          -  patients aged 18-60 with keratoconus undergoing CXL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  outside age range&#xD;
&#xD;
          -  history of previous ocular surgeries&#xD;
&#xD;
          -  unable to cooperate for the Brillouin microscopic examination&#xD;
&#xD;
          -  unable to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Cleveland Clinic Cole Eye Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zhang H, Roozbahani M, Piccinini AL, Golan O, Hafezi F, Scarcelli G, Randleman JB. Depth-Dependent Reduction of Biomechanical Efficacy of Contact Lens-Assisted Corneal Cross-linking Analyzed by Brillouin Microscopy. J Refract Surg. 2019 Nov 1;35(11):721-728. doi: 10.3928/1081597X-20191004-01.</citation>
    <PMID>31710374</PMID>
  </reference>
  <reference>
    <citation>Webb JN, Langille E, Hafezi F, Randleman JB, Scarcelli G. Biomechanical Impact of Localized Corneal Cross-linking Beyond the Irradiated Treatment Area. J Refract Surg. 2019 Apr 1;35(4):253-260. doi: 10.3928/1081597X-20190304-01.</citation>
    <PMID>30984983</PMID>
  </reference>
  <reference>
    <citation>Randleman JB, Su JP, Scarcelli G. Biomechanical Changes After LASIK Flap Creation Combined With Rapid Cross-Linking Measured With Brillouin Microscopy. J Refract Surg. 2017 Jun 1;33(6):408-414. doi: 10.3928/1081597X-20170421-01.</citation>
    <PMID>28586502</PMID>
  </reference>
  <results_reference>
    <citation>Scarcelli G, Pineda R, Yun SH. Brillouin optical microscopy for corneal biomechanics. Invest Ophthalmol Vis Sci. 2012 Jan 20;53(1):185-90. doi: 10.1167/iovs.11-8281.</citation>
    <PMID>22159012</PMID>
  </results_reference>
  <results_reference>
    <citation>Scarcelli G, Kling S, Quijano E, Pineda R, Marcos S, Yun SH. Brillouin microscopy of collagen crosslinking: noncontact depth-dependent analysis of corneal elastic modulus. Invest Ophthalmol Vis Sci. 2013 Feb 19;54(2):1418-25. doi: 10.1167/iovs.12-11387.</citation>
    <PMID>23361513</PMID>
  </results_reference>
  <results_reference>
    <citation>Scarcelli G, Besner S, Pineda R, Yun SH. Biomechanical characterization of keratoconus corneas ex vivo with Brillouin microscopy. Invest Ophthalmol Vis Sci. 2014 Jun 17;55(7):4490-5. doi: 10.1167/iovs.14-14450.</citation>
    <PMID>24938517</PMID>
  </results_reference>
  <results_reference>
    <citation>Scarcelli G, Besner S, Pineda R, Kalout P, Yun SH. In vivo biomechanical mapping of normal and keratoconus corneas. JAMA Ophthalmol. 2015 Apr;133(4):480-2. doi: 10.1001/jamaophthalmol.2014.5641.</citation>
    <PMID>25611213</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>James Bradley Randleman</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <keyword>Brillouin</keyword>
  <keyword>Keratoconus</keyword>
  <keyword>Keratoconus, Unstable</keyword>
  <keyword>Corneal Cross Linking</keyword>
  <keyword>CXL</keyword>
  <keyword>LASIK</keyword>
  <keyword>PRK</keyword>
  <keyword>SMILE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>there is no plan to share data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

